Plga nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: A novel approach towards reduction of renal radiation dose

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Arora, Geetanjali ^a   Shukla, Jaya ^b   Ghosh, Sourabh ^c   Maulik, Subir Kumar ^a   Malhotra, Arun ^a   Bandopadhyaya, Gurupad ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DOTATATE LU 177; POLYGLACTIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; DRUG DERIVATIVE; LACTIC ACID; NANOPARTICLE; OCTREOTIDE; ORGANOMETALLIC COMPOUND; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SOMATOSTATIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG COATING; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LIVER; NEUROENDOCRINE TUMOR; NONHUMAN; PARTICLE SIZE; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; RADIATION DOSE; RADIOISOTOPE DISTRIBUTION; RAT; ANIMAL; WISTAR RAT;

RATTUS;

ANIMALS; KIDNEY; LACTIC ACID; NANOPARTICLES; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POLYGLYCOLIC ACID; RADIATION DOSAGE; RATS; RATS, WISTAR; RECEPTORS, SOMATOSTATIN;

EID: 84858612966     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034019     Document Type: Article

References (34)

1. Paganelli Giovanni, Bodei Lisa, (2007) Neuroendocrine Tumors. IEO - Scientific Report.
2. Vegt Erik, de Jong Marion, Wetzels JackFM, Masereeuw Rosalinde, Melis Marleen, et al. (2010) Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51: 1049-1058.
3. Gnanasegaran G, Kapse N, Buscombe JR, (2005) Recent Trends in Radionuclide Imaging and Targeted Radionuclide Therapy of Neuroendocrine Tumors. Indian J Nucl Med 20: 55-66.
4. Noemi Bronstein-Sitton (2006) Somatostatin and the Somatostatin Receptors: Versatile Regulators of Biological Activity. Pathways No. 2 Spring 2006.
5. Kairemo Kalevi, Erba Paola, Bergstrom Kim, Pauwels ErnestKJ, (2008) Nanoparticles in Cancer. Curr Radiopharm 1: 30-36.
6. Ting Gann, Chang Chih-Hsien, Wang Hsin-Ell, Lee Te-Wei, (2010) Nanotargeted Radionuclides for Cancer Nuclear Imaging and Internal Radiotherapy. J Biomed Biotechnol 2010: 1-17.
7. Das Tapas, Chakraborty Sudipta, Kallur KumarG, Venkatesh Meera, Banerjee Sharmila, (2011) Preparation of Patient Doses of 177Lu-DOTA-TATE Using Indigenously Produced 177Lu: The Indian Experience. Cancer Biother Radiopharm 26: 395-400.
8. Shukla Jaya, Bandopadhyaya Guru Pad, Varma Indira Kumari, Kumar Rakesh, Maulik Subir Kumar, (2007) Morphology Based Release Kinetics of 99mTc(V) DMSA Loaded PLGA Microspheres as Targeted Radiotherapeutic Model. Hell J Nucl Med 10: 9-13.
9. Mohanraj VJ, Chen Y, (2006) Nanoparticles - A Review. Trop J Pharm Res 5: 561-573.
10. Harrington KevinJ, Mohammadtaghi Sima, Uster PaulS, Glass Daphne, Peters AMichael, et al. (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7: 243-254.
11. Wang SeanX, Bao Ande, Herrera StephanieJ, Phillips WT, Goins B, et al. (2008) Intraoperative 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model. Clin Cancer Res 14: 3975-83.
12. Muthu MS, (2009) Nanoparticles based on PLGA and its copolymer: An overview. Asian J Pharm 3: 266-273.
13. Budhian Avinash, Siegel StevenJ, Winey KarenI, (2007) Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int J Pharm 336: 367-375.
14. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MNV, (2009) Design of biodegradable nanoparticles for oral delivery of Doxorubicin: In vivo pharmacokinetics and toxicity studies in rats. Pharm res 26: 492-501.
15. Sameni J, Bukhari NI, Azlan NA, Julianto T, Majeed ABA, (2009) The Effect of Preparation Parameters on the Size and Morphology of PLGA-Based Nanoparticle. IEEE Symposium on Industrial Electronics and Applications (ISIEA 2009). October 4-6, 2009, Kuala Lumpur, Malaysia.
16. Lee Seung Chan, Oh Jae Taek, Jang Myoung Ho, Chung Soo Il, (1999) Quantitative analysis of polyvinyl alcohol on the surface of poly(D,L-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration. J control Release 59: 123-132.
17. Dadashzadeh S, Vali AM, Rezaie M, (2008) The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Intl J Pharm 353: 251-259.
18. Park Jason, Fong Peter M, Lu Jing, Russell Kerry S, Boothetal CarmenJ, et al. (2009) PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomed Nanotech Biol Med 5: 410-418.
19. Coating layered nanoparticles alters immune cell uptake. Nano Werk. Posted online: September 11, 2006, Source: National Cancer Institute.
20. De Sinjan, Robinson DennisH, (2004) Particle Size and Temperature Effect on the Physical Stability of PLGA Nanospheres and Microspheres Containing Bodipy. AAPS Pharm Sci Tech 5: Article 53.
21. Nakano K, Bando Y, Tozuka Y, Takeuchi H, (2007) Cellular interaction of PEGylated PLGA nanospheres with macrophage J774 cells using flow cytometry. Asian J Pharm Sci 2: 220-226.
22. Tiyaboonchai Waree, (2003) Chitosan Nanoparticles: A Promising System for Drug Delivery. Naresuan University Journal 11: 51-66.
23. Mao Shirui, Xu Jing, Cai Cuifang, Germershaus Oliver, Schaper Andreas, et al. (2007) Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. Int J Pharm 334: 137-148.
24. Barichello Jose Mario, Morishita Mariko, Takayama Kozo, Nagai Tsuneji, (1999) Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 25: 471-476.
25. Govender Thirumala, Stolnik Snjezana, Garnett MartinC, Illum Lisbeth, Davis StanleyS, (1999) PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 57: 171-185.
26. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V, (2004) Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci 93: 1804-14.
27. Targeted Radionuclide Therapy (2010) Ebook by Tod W. Speer; ISBN/ISSN: 9780781796934.
28. Vaidyanathan Ganesan, Friedman HenryS, Affleck DonnaJ, Schottelius M, Wester HJ, et al. (2003) Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin Can Res 9: 1868-1876.
29. Li Ya-Ping, Pei Yuan-Ying, Zhang Xian-Ying, Gu Zhou-Hui, Zhou Zhao-Hui, et al. (2001) PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release 71: 203-211.
30. Wu Yan, Yang Wuli, Wang Changchun, Hu Jianhua, Fu Shoukuan, (2005) Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm 295: 235-245.
31. DeNardo SallyJ, DeNardo GeraldL, Natarajan Arutselvan, Miers LA, Foreman AR, et al. (2007) Thermal Dosimetry Predictive of Efficacy of 111In-ChL6 Nanoparticle AMF-Induced Thermoablative Therapy for Human Breast Cancer in Mice. J Nucl Med 48: 437-444.
32. Rossin Raffaella, Pan Dipanjan, Qi Kai, Turner JeffreyL, Sun Xiankai, et al. (2005) 64Cu-Labeled Folate-Conjugated Shell Cross- Linked Nanoparticles for Tumor Imaging and Radiotherapy: Synthesis, Radiolabeling, and Biologic Evaluation. J Nucl Med 46: 1210-1218.
33. Kaul Goldie, Amiji Mansoor, (2004) Biodistribution and targeting potential of poly (ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target 12: 585-591.
34. Xie Jin, Xu Chenjie, Kohler Nathan, Hou Yanglong, Sun Shouheng, (2007) Controlled PEGylation of Monodisperse Fe3O4 Nanoparticles for Reduced Non-Specific Uptake by Macrophage Cells. Adv Mater 19: 3163-3166.